Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo pill shows promise for stubborn high blood pressure

NCT ID NCT06236061

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding amlodipine to the blood pressure drug LCZ696 works better than LCZ696 alone. About 718 adults with mild-to-moderate high blood pressure that wasn't well controlled by LCZ696 took part. The goal was to see if the combination lowers blood pressure more effectively over 8 weeks, with a long-term follow-up for safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension follicular lymphoma hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION

Contacts and locations

Locations

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4518511, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 453-0804, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4540933, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4578511, Japan

  • Novartis Investigative Site

    Itoshima, Fukuoka, 8191104, Japan

  • Novartis Investigative Site

    Chitose, Hokkaido, 066-0032, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 30026, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 630826, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 630842, Japan

  • Novartis Investigative Site

    Akashi, Hyōgo, 674-0081, Japan

  • Novartis Investigative Site

    Amagasaki, Hyōgo, 660-0861, Japan

  • Novartis Investigative Site

    Tsukuba, Ibaraki, 3050861, Japan

  • Novartis Investigative Site

    Kamakura, Kanagawa, 247-0055, Japan

  • Novartis Investigative Site

    Kawasaki-shi, Kanagawa, 211-0041, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 231-0023, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 232-0064, Japan

  • Novartis Investigative Site

    Ōsaki, Miyagi, 989-6143, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 980-0011, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 9830039, Japan

  • Novartis Investigative Site

    Suita, Osaka, 5650853, Japan

  • Novartis Investigative Site

    Chiyoda City, Tokyo, 101-0041, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 104-0031, Japan

  • Novartis Investigative Site

    Chuo-ku, Tokyo, 1030027, Japan

  • Novartis Investigative Site

    Hachiōji, Tokyo, 192-0046, Japan

  • Novartis Investigative Site

    Kiyose, Tokyo, 204-0021, Japan

  • Novartis Investigative Site

    Musashino, Tokyo, 1800022, Japan

  • Novartis Investigative Site

    Nerima Ku, Tokyo, 1770051, Japan

  • Novartis Investigative Site

    Setagaya-ku, Tokyo, 1550031, Japan

  • Novartis Investigative Site

    Shibuya City, Tokyo, 150-0013, Japan

  • Novartis Investigative Site

    Shinagawa-Ku, Tokyo, 141-0032, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 160-0008, Japan

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, 1600017, Japan

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, 1690072, Japan

  • Novartis Investigative Site

    Suginami-ku, Tokyo, 166-0003, Japan

  • Novartis Investigative Site

    Toshima-Ku, Tokyo, 171-0021, Japan

  • Novartis Investigative Site

    Chuoh-ku, 104-0031, Japan

  • Novartis Investigative Site

    Fukuoka, 810-0021, Japan

  • Novartis Investigative Site

    Hiroshima, 732-0053, Japan

  • Novartis Investigative Site

    Kyoto, 615-8125, Japan

  • Novartis Investigative Site

    Osaka, 5300002, Japan

  • Novartis Investigative Site

    Osaka, 5320003, Japan

  • Novartis Investigative Site

    Osaka, 536-0008, Japan

  • Novartis Investigative Site

    Osaka, 550-0013, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.